COVID THERAPEUTICS FOR OUTPATIENTS AT HIGH RISK OF SEVERE COVID-19

Quick Reference for Long Term Care Prescribers

What therapeutic options are available for COVID positive patients?

Therapeutic	Reduction In hospitalization & death	Route	Treatment Initiation from Symptom Onset	Treatment Duration	OMASS Requirement	Considerations	Preference
						Patients age 12+ and ≥ 40kg	
Paxlovid (Nirmatrelvir/						Multiple drug interactions	
Ritonavir) 300mg/100mg	88%	Oral	Within 5 days	5 days	Score 3+	Adjust dosing for renal impairment	1 st Tier
po BID x 5days						Not recommended in severe hepatic impairment	
Remdesivir	87%	IV	Within 7 days	3 days (1-2 hr)	Score 3+	Patients ≥ 3.5kg Renal and hepatic	1 st Tier
						considerations	
Sotrovimab	85%	IV	Within 10 days	30 minutes	Score 3+	Patients age 12+ and ≥ 40kg	2 nd Tier Reserve use for those whom: Paxlovid & Remdesivir are contraindicated or unavailable Outside treatment
							window for Paxlovid & Remdesivir
Molnupiravir 200mg 4 tabs po BID x 5 days	30%	Oral	Within 5 days	5 days	Score 1+	Patients age 18+	3 rd Tier
						Not recommended in pregnancy	Utilize for OMASS
						Contraceptive recommendations for males and females.	3+ only if other treatment options are unavailable

How do I know when the patient eligibility criteria have changed?

Check the link below for the current prescribing criteria. They will expand to include all patients eligible under the EUA as supply increases. https://cv.nmhealth.org/providers/covid-19-oral-therapeutics-information-for-providers/

How do I prescribe COVID therapeutics?

- Please include date of symptom onset and OMASS score. It helps the pharmacy staff when processing prescriptions.
- The contracted long term care pharmacy should have Sotrovimab, Paxlovid, and Molnupiravir in stock.
- If your LTC Pharmacy is out of oral medications, Community Walgreens #16544 can overnight medications directly to the patient's residence. Community is open Monday-Friday. Weekend orders after Friday at 4pm must be sent to the nearest drive-thru location for pick up.
- If your LTC pharmacy is out of Sotrovimab, you can contact Contigo Pharmacy 505-677-8842, Vital Care 575-636-1570, One Care Infusion Pharmacy 505-726-4155, Highland Pharmacy 505-243-3777 or Advanced Medication Management System 575-885-2979.


QUESTIONS? EMAIL COVID.THERAPEUTICS@STATE.NM.US

Oral Antiviral & Monoclonal Antibody Screening Score (OMASS)

adapted from Mayo Clinic's published Monoclonal Antibody Screening Score (MASS)

RISK FACTOR	POINTS					
Age 65 years and older						
BMI 35 kg/m2 and higher						
Diabetes mellitus						
Chronic kidney disease						
Cardiovascular disease in a patient 55 years and older						
Chronic respiratory disease in a patient 55 years and older	3					
Hypertension in a patient 55 years and older						
Immunosuppressed and unlikely to have responded to vaccines (eg: CD20 inhibitors, BTK inhibitors, campath, recent CAR-T, organ transplant)	3					
Pregnancy*,	4					
BIPOC (Black, Indigenous, People of Color) status	1					
Any other underlying medical condition associated with high risk for severe COVID-19 disease according to the CDC	1					

^{*}Molnupiravir is not recommended for use in pregnancy.



Limited use of bamlanivimab/etesevimab and REGEN-COV as they are not expected to be active against the Omicron variant¹

Remdesivir is only approved for hospitalized individuals with COVID-19. Outpatient treatment is based on information from the literature (Dec 22, 2021 Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients; DOI: 10.1056/NEJMoa2116846) 2 COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies is authorized for the treatment of COVID-19 in patients with immunosuppressive disease in either the outpatient or inpatient setting (COVID-19 Convalescent Plasma EUA)